Shopping Cart
Remove All
Your shopping cart is currently empty
Olmesartan
😃Good
Catalog No. T5964Cas No. 144689-24-7
Alias RNH 6270, CS 088
Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity.
Olmesartan
😃Good
Purity: 99.81%
Catalog No. T5964Alias RNH 6270, CS 088Cas No. 144689-24-7
Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $39 | In Stock | In Stock | |
| 50 mg | $64 | In Stock | In Stock | |
| 100 mg | $98 | - | In Stock | |
| 500 mg | $262 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $43 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.81%
Appearance:Solid
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Olmesartan (RNH 6270) is an Angiotensin II Type I receptor antagonist. Olmesartan is the active form of the antihypertensive drug olmesartan medoxomil,and has antihypertensive activity. |
| In vivo | The target blood pressure (<130/80 mm Hg) was achieved in nearly 80% of the patients taking olmesartan and 71% taking placebo;?blood pressure measured in the clinic was lower by 3.1/1.9 mm Hg in the olmesartan group than in the placebo group.?Microalbuminuria developed in 8.2% of the patients in the olmesartan group (178 of 2160 patients who could be evaluated) and 9.8% in the placebo group (210 of 2139);?the time to the onset of microalbuminuria was increased by 23% with olmesartan (hazard ratio for onset of microalbuminuria, 0.77;?95% confidence interval, 0.63 to 0.94;?P=0.01).?The serum creatinine level doubled in 1% of the patients in each group.?Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events--81 of 2232 patients (3.6%) as compared with 91 of 2215 patients (4.1%) (P=0.37)--but a greater number had fatal cardiovascular events--15 patients (0.7%) as compared with 3 patients (0.1%) (P=0.01),?a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2.0%] vs. 1 of 540 [0.2%], P=0.02)[1]. |
| Animal Research | In a randomized, double-blind, multicenter, controlled trial, Assigned 4447 patients with type 2 diabetes to receive olmesartan (at a dose of 40 mg once daily) or placebo for a median of 3.2 years.?Additional antihypertensive drugs (except angiotensin-converting-enzyme inhibitors or ARBs) were used as needed to lower blood pressure to less than 130/80 mm Hg. The primary outcome was the time to the first onset of microalbuminuria.?The times to the onset of renal and cardiovascular events were analyzed as secondary end points[1]. |
| Synonyms | RNH 6270, CS 088 |
| Molecular Weight | 446.50 |
| Formula | C24H26N6O3 |
| Cas No. | 144689-24-7 |
| Smiles | C(N1C(C(O)=O)=C(C(C)(C)O)N=C1CCC)C2=CC=C(C=C2)C3=C(C=CC=C3)C=4NN=NN4 |
| Relative Density. | 1.33 g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | DMSO: 6.25 mg/mL (14.00 mM), Sonication is recommended.  | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.00 mg/mL (2.24 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Olmesartan | purchase Olmesartan | Olmesartan cost | order Olmesartan | Olmesartan chemical structure | Olmesartan in vivo | Olmesartan formula | Olmesartan molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.